multicentee randomized controlled study of azathioprine versus iterferon beta in relapsing remitting multiple sclerosis - M.A.I.N. trial

niversita di Firenze0 个研究点开始时间: 2007年7月4日最近更新: 2012年3月19日

适应症

试验速览

暂无简介。

•age 18-55 years; diagnosis of multiple sclerosis McDonald criteria 2001 with relapsin remitting course; at least 2 exacerbation in the preceding 2 years;Baseline EDSS score of 1 to 5,5; no clinical relapses within 30 days of study entry;effective method of contraception if women with childbearing potential; signed informed patient consent.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) no
•F.1.3.1 Number of subjects for this age range

•immunomodulatory or immunosoppressive tratments in the preceding 6 mounths; steroid therapy in the last 30 days before study entry; concomitant diseases precluding interferon beta or azathioprine treatment; pregnancy or breastfeeding; inability to give the informed consent; pathological conditions interfering with multiple sclerosis evolution; allergy to paracetamol or known intolerance to azathioprine or interferon beta.

发起方

niversita di Firenze